Ivan Serrano Santiago, MD
Endocrinology, Diabetes & Metabolism · Caguas, PRNPI 1952763476
Payments from drug & device makers
Across 188 payments — averaging $29.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Novo Nordisk$872
- Eli Lilly Export S.A. Puerto Rico Branch$835
- Boehringer Ingelheim$487
- Lilly USA, LLC$300
- Abbott$273
- plus $2K from 10 others
What the payments were for
- Travel & lodging$5099%
- Food & beverage$5,03891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 22 | $1,274 |
| Novo Nordisk | 41 | $872 |
| Eli Lilly Export S.A. Puerto Rico Branch | 36 | $835 |
| Boehringer Ingelheim | 14 | $487 |
| Lilly USA, LLC | 7 | $300 |
| Abbott | 13 | $273 |
| Amgen(2 entities) | 9 | $267 |
| AstraZeneca | 3 | $265 |
| Dexcom, Inc. | 15 | $261 |
| Sanofi-aventis U.S. LLC | 11 | $243 |
| Bayer Puerto Rico Inc. | 7 | $164 |
| BETA Bionics, Inc. | 1 | $116 |
| Radius Health, Inc. | 3 | $75 |
| Merck | 3 | $52 |
| Bayer | 2 | $49 |
| Vifor Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$474
- iLet Bionic Pancreas$347
- FARXIGA$242
- MINIMED 770G$127
- TEPEZZA$119
- MOUNJARO$119
- iLet Insulin Infusion Kit Inset$116
- iLet Insulin Infusion Kit Contact Detach$116
- Ozempic$112
How this compares
$5,547 in reported general payments places this provider in the 50th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
See all endocrinology, diabetes & metabolism providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 516 | $517,907 |
| TrulicityDulaglutide | 258 | $280,305 |
| MounjaroTirzepatide | 146 | $155,906 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 168 | $107,589 |
| JardianceEmpagliflozin | 136 | $99,175 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 140 | $89,297 |
| FarxigaDapagliflozin Propanediol | 100 | $66,574 |
| Jentadueto XrLinagliptin/Metformin Hcl | 116 | $61,643 |
| TradjentaLinagliptin | 76 | $43,392 |
| GlyxambiEmpagliflozin/Linagliptin | 56 | $40,495 |
| SynthroidLevothyroxine Sodium | 512 | $30,785 |
| LantusInsulin Glargine,hum.Rec.Anlog | 176 | $20,708 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 21 | $18,726 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 33 | $17,848 |
| Xigduo XrDapaglifloz Propaned/Metformin | 19 | $15,757 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $872 | $517,907516 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30, Insulin Lispro | $300 | $456,270576 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Trijardy Xr, Jentadueto Xr, Tradjenta | $487 | $441,590692 claims |
| AstraZenecaFarxiga | $265 | $66,574100 claims |
| Sanofi-aventis U.S. LLCLantus, Soliqua 100-33 | $243 | $39,434197 claims |
| MerckJanumet Xr | $52 | $17,84833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
Other endocrinology, diabetes & metabolism in Caguas
- Wilfredo BravoCaguas$767K
- Juan OteroCaguas$452K
- Nicolle Canales RamosCaguas$12K
- Ivan Laboy OrtizCaguas$9K
- Edna Melendez ReyesCaguas$9K
- Alberto Grana SantiniCaguas$8K
- Angel Comulada RiveraBayamon$8.9M
- Ramon Ortiz CarrasquilloManati$6M
- Alex Gonzalez BossoloSan Juan$5.5M
- Martha GomezSan Juan$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.